Showing results (141-150 of 186) with videos related to
Sort By:
Pageof 19
The Journal of Biological Chemistry|September 18, 2004
Tau becomes a more favorable substrate for GSK-3 when it is prephosphorylated by PKA in rat brainShi Jie Liu, Jia Yu Zhang, Hong Lian Li, et al.Research and Practice in Thrombosis and Haemostasis|September 13, 2023
Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in ChinaHeng Mei, Hu Zhou, Ming Hou, et al.Cytotherapy|April 19, 2023
Bruton tyrosine kinase inhibitors preserve anti-CD19 chimeric antigen receptor T-cell functionality and reprogram tumor micro-environment in B-cell lymphomaWenjing Luo, Chenggong Li, Jianghua Wu, et al.Microorganisms|March 28, 2026
Construction of a Three-Dimensional Culture Model of HSV-1 Based on the Nano-Self-Assembling Peptide RADA16-I and Preliminary Exploration of the Relationship Between HSV-1 and AutophagyZhen Hu, Yun-E Xu, Jie Zhang, et al.Journal for Immunotherapy of Cancer|May 27, 2024
Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in ChinaWenyan Yu, Liang Huang, Heng Mei, et al.Frontiers in Immunology|June 11, 2021
<i>PiggyBac</i>-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case ReportChenggong Li, Yan Sun, Jing Wang, et al.The Lancet. Haematology|July 14, 2020
Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort studyDanying Liao, Fen Zhou, Lili Luo, et al.Leukemia|October 17, 2023
Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myelomaChenggong Li, Jia Xu, Wenjing Luo, et al.Thrombosis Research|November 11, 2025
Bone marrow blasts- and modified EASIX-guided risk stratification for coagulopathy and outcomes after CAR-T therapy in relapsed/refractory B-ALLYingying Li, Jiachen Liu, Lili Luo, et al.Blood Cancer Journal|April 24, 2023
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignanciesYinqiang Zhang, Chenggong Li, Mengyi Du, et al.Pageof 19